Perspective Therapeutics (CATX) Operating Expenses (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of Operating Expenses data on file, last reported at $28.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 27.88% year-over-year to $28.4 million; the trailing twelve-month figure through Mar 2026 stood at $28.4 million (down 71.97% YoY), and the FY2025 full-year result was $114.4 million, up 23.94% from the prior year.
• Operating Expenses climbed to $28.4 million in Q1 2026, from $22.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $45.2 million in Q4 2024 to a low of $2.8 million in Q1 2022.
• A 5-year average of $15.0 million and a median of $11.2 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses slipped 4.25% in 2023 and jumped 276.41% in 2024, its largest moves.
• Tracing CATX's Operating Expenses over 5 years: stood at $5.6 million in 2022, then jumped by 113.72% to $12.0 million in 2023, then jumped by 276.41% to $45.2 million in 2024, then plunged by 50.96% to $22.2 million in 2025, then advanced by 27.88% to $28.4 million in 2026.
• Business Quant data shows CATX's Operating Expenses at $28.4 million in Q1 2026, $22.2 million in Q1 2025, and $45.2 million in Q4 2024.